VivoSim Labs, Inc. is a biotechnology company dedicated to developing sophisticated 3D tissue models designed to replicate key aspects of human diseases. At the heart of their operations is a proprietary 3D human tissue platform, which incorporates their advanced NovoGen Bioprinters. These automated devices are engineered to construct intricate 3D living tissues using mammalian cells, alongside complementary technologies vital for preparing specialized bio-inks and for the precise bioprinting of multi-cellular tissues with complex architectural designs. The company's leading therapeutic prospect, FXR314, is currently undergoing a Phase 2/3 clinical trial for inflammatory bowel disease, with a specific focus on ulcerative colitis. Furthermore, FXR314 has successfully completed a Phase 1 clinical trial investigating its efficacy for liver fibrosis, particularly steatohepatitis. VivoSim Labs maintains active research collaborations concerning its NovoGen Bioprinters with prestigious institutions such as the Yale School of Medicine, the Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia. Established in 2007 and headquartered in San Diego, California, the company previously operated under the name Organovo Holdings, Inc. before officially rebranding to VivoSim Labs, Inc. in April 2025.
